drug
zilucoplan
Marketedupdated 3mo agoby UCB SA
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 2all catalysts(6)
approval · 6
Oct 17, 2023
approval
ZILBRYSQ (ZILUCOPLAN SODIUM) — FDA approval
zilucoplan
→
Jan 16, 2024
approval
ZILBRYSQ (ZILUCOPLAN SODIUM) — FDA approval
zilucoplan
→
Apr 26, 2024
approval
ZILBRYSQ (ZILUCOPLAN SODIUM) — FDA approval
zilucoplan
→
Feb 28, 2025
approval
ZILBRYSQ (ZILUCOPLAN SODIUM) — FDA approval
zilucoplan
→
Feb 28, 2025
approval
ZILBRYSQ (ZILUCOPLAN SODIUM) — FDA approval
zilucoplan
→
Jan 22, 2026
approval
ZILBRYSQ (ZILUCOPLAN SODIUM) — FDA approval
zilucoplan
→
Trials studying zilucoplan
- phase3A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis
- phase3Open-Label Extension of Zilucoplan in Subjects With Generalized Myasthenia Gravis
- phase3An Open-label Extension Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis
- phase3A Study to Evaluate the Safe and Effective Use of a Zilucoplan Auto-injector by Study Participants With Generalized Myasthenia Gravis
- phase1A Study to Assess Zilucoplan Concentration in Breast Milk of Healthy Lactating Women
- phase3Zilucoplan for Severe gMG Exacerbations
- phase1A Study to Evaluate Zilucoplan Injected Subcutaneously Either by a Prefilled Syringe or an Auto-injector in Healthy Adult Participants
- phase3An Open-label Study to Evaluate the Safety, Tolerability, and Efficacy of Subcutaneous Zilucoplan in Participants With Generalized Myasthenia Gravis Who Were Previously Receiving Intravenous Complement Component 5 Inhibitors
Patent cliff
source: FDA Orange Bookfirst barrier falls
Oct 17, 2028
~2.2 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (27)
- Jun 12, 2035compositionUS 10106579
- Jun 12, 2035compositionUS 10106579
- Jun 12, 2035compositionUS 10106579
- Jun 12, 2035compositionUS 10208089
- Jun 12, 2035compositionUS 10208089
- Jun 12, 2035compositionUS 10208089
- Jun 12, 2035compositionUS 10435438
- Jun 12, 2035compositionUS 10435438
- Jun 12, 2035compositionUS 10435438
- Jun 12, 2035compositionUS 10562934
- Jun 12, 2035compositionUS 10562934
- Jun 12, 2035compositionUS 10562934
- Jun 12, 2035formulationUS 10835574
- Jun 12, 2035formulationUS 10835574
- Jun 12, 2035formulationUS 10835574
- Jun 12, 2035compositionUS 11014965
- Jun 12, 2035compositionUS 11014965
- Jun 12, 2035compositionUS 11014965
- Jun 12, 2035formulationUS 11535650
- Jun 12, 2035formulationUS 11535650
- Jun 12, 2035formulationUS 11535650
- Jun 12, 2035formulationUS 11752190
- Jun 12, 2035formulationUS 11752190
- Jun 12, 2035formulationUS 11752190
- Jun 12, 2035formulationUS 11965040
- Jun 12, 2035formulationUS 11965040
- Jun 12, 2035formulationUS 11965040
FDA exclusivities (6)
- Oct 17, 2030ODE-446Orphan Drug (7y)4.2y
- Oct 17, 2030ODE-446Orphan Drug (7y)4.2y
- Oct 17, 2030ODE-446Orphan Drug (7y)4.2y
- Oct 17, 2028NCENew Chemical Entity (5y)2.2y
- Oct 17, 2028NCENew Chemical Entity (5y)2.2y
- Oct 17, 2028NCENew Chemical Entity (5y)2.2y
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 21m ago
Found something off?
comments(0)
5-min edit window · permanent after that